News AZ’s Bydureon disappoints in diabetes outcomes trial Results give advantage to Boehringer/Lilly's Jardiance.
News Semaglutide could transform diabetes treatment, revive Novo ... Oral formulation of GLP-1 drug could help cut heart attacks, tackle liver and kidney problems
News Novo Nordisk board member quits over NASH conflict of intere... Mary Szela has quit to avoid a conflict of interest.
News Novo enjoys strong Q1 as Trump price crackdown fails to mate... Novo Nordisk has shaken off fears of a drug pricing crackdown from president Donald Trump, after it beat profit forecasts in Q1 results.
News Keytruda in new lymphoma use leads latest CHMP decisions MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
